What TargetGene Biotechnologies does

TargetGene Biotechnologies Ltd. is a private Israeli biotechnology company founded in 2012 and headquartered in Rehovot, operating with a 1-10 employee team under founders Dan Weinthal and Yoel Shiboleth. The company develops a proprietary gene-editing technology platform intended for application in next-generation cell therapies.

The company's core product is its gene-editing technology, which is being integrated with Kadimastem's cell therapy platforms through a strategic collaboration announced on 2025-10-27 alongside NLS Pharmaceutics Ltd. The collaboration targets the development of gene-edited cell therapies for serious diseases, specifically ALS and diabetes, and is structured to proceed under the combined entity NewCelX, formed from the merger of NLS and Kadimastem.

TargetGene's revenue model, pricing, and funding history are not publicly disclosed, and the company has no parent organization or listed subsidiaries. Its near-term commercial pathway is concentrated in the NewCelX collaboration, which provides the scale, clinical development infrastructure, and listed-entity access that TargetGene itself lacks. The company's operating status is active as of October 2025, and its primary customer segment is healthcare providers and biotechnology companies developing cell-based therapies for neurodegenerative and metabolic diseases.

Name

TargetGene Biotechnologies

Legal name

TargetGene Biotechnologies Ltd.

Website

https://targetgenebio.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

TargetGene Biotechnologies is an Israel-based, privately held biotech developing proprietary gene-editing technology for next-generation cell therapies, collaborating with NLS Pharmaceutics and Kadimastem to treat ALS and diabetes under NewCelX.

Ownership category

akta.pro rank

Product category

Gene Editing Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Gene-editing technology
• Cell therapy development
• Biotechnology research
• Genetic engineering services
• Precision medicine platforms

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

TargetGene Biotechnologies develops and provides a proprietary gene-editing technology platform used to engineer next-generation gene-edited cell therapies. The technology is being integrated with cell therapy platforms through strategic collaborations to create treatments for serious diseases such as ALS and diabetes.

Differentiator

Problem solved

Functional benefit

Products and services

• Gene-Editing Technology TargetGene's proprietary gene-editing technology platform designed for developing next-generation gene-edited cell therapies. The technology is being integrated with Kadimastem's cell therapy platforms to create treatments for diseases such as ALS and diabetes.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• NLS Pharmaceutics Ltd.coreStrategic or Co-development Partner · 27 October 2025Strategic collaboration between NLS Pharmaceutics, Kadimastem, and TargetGene to develop next-generation gene-edited cell therapies. The collaboration will proceed under the combined company NewCelX after a merger between NLS and Kadimastem. The partnership integrates TargetGene's gene-editing technology with Kadimastem's cell therapy platforms to create safer, more effective treatments for diseases such as ALS and diabetes.
• Kadimastem Ltd.coreStrategic or Co-development Partner · 27 October 2025Strategic collaboration to develop next-generation gene-edited cell therapies by integrating Kadimastem's cell therapy platforms with TargetGene's gene-editing technology. The combined company NewCelX (formed from merger of NLS and Kadimastem) will advance these therapies targeting ALS and diabetes. Kadimastem provides cell therapy platforms while TargetGene contributes gene-editing technology.

Recent moves2 records

Expansion highlights4 records

Direct peers

• Cellectis: Cellectis is a clinical-stage gene-editing and cell therapy company using TALEN-based editing for allogeneic CAR-T and other cell therapies. Highly comparable to TargetGene as it sits at the same intersection of gene editing and cell therapy platforms.
• Editas Medicine: Editas Medicine develops CRISPR-based genome editing medicines for diseases of the eye, blood, and oncology. It is comparable to TargetGene as a pure-play gene-editing platform company pursuing multiple in vivo and ex vivo therapeutic applications.
• BrainStorm Cell Therapeutics: BrainStorm Cell Therapeutics is an Israeli cell therapy company developing autologous cell therapies for neurodegenerative diseases, including ALS. Highly comparable to TargetGene's ALS and cell therapy focus, and to its Israeli operating base.
• CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene-editing company developing CRISPR/Cas9-based therapeutics across hemoglobinopathies, oncology, and regenerative medicine. It is the most directly comparable peer to TargetGene as both operate gene-editing platforms applied to serious diseases, with TargetGene differentiated by its cell-therapy integration focus.
• Beam Therapeutics: Beam is a precision genetic medicines company developing base-editing therapeutics. It is a direct peer to TargetGene in the gene-editing technology category, with both companies building novel editing modalities for serious disease indications.
• Caribou Biosciences: Caribou Biosciences develops CRISPR-based genome-edited allogeneic cell therapies for oncology. It is comparable to TargetGene as a clinical-stage company applying gene-editing technology to engineered cell therapies.
• Intellia Therapeutics: Intellia is a clinical-stage gene-editing company applying both in vivo and ex vivo CRISPR/Cas9 approaches to oncology, autoimmune, and genetic disease. Comparable as a gene-editing platform operator with a similar cell therapy and broader therapeutic reach.
• Kadimastem Ltd. Kadimastem is an Israeli cell therapy company developing cell-based treatments for ALS and diabetes. It is TargetGene's named collaboration partner within NewCelX, and the two companies are explicitly being combined to integrate cell therapy platforms with TargetGene's gene-editing capabilities.

Emerging players

• Verve Therapeutics: Verve Therapeutics develops in vivo gene-editing medicines targeting cardiovascular disease. Comparable to TargetGene as a clinical-stage gene-editing platform company, though Verve focuses on in vivo lipid nanoparticle delivery rather than cell therapy.
• Prime Medicine: Prime Medicine is developing prime editing, a next-generation gene-editing technology. Comparable to TargetGene as an early-to-mid-stage platform company exploring novel editing modalities for serious genetic diseases.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/3216766

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TargetGene Biotechnologies